Notice: This company has been marked as potentially delisted and may not be actively trading. G1 Therapeutics (GTHX) News Today Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Drug developer seeks $100M for new cancer treatmentDecember 20 at 9:39 AM | bizjournals.comPharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender OfferSeptember 18, 2024 | globenewswire.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Shares Purchased by Acadian Asset Management LLCAcadian Asset Management LLC boosted its stake in shares of G1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) by 114.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 928,205 shares of the company's stock after buyingSeptember 15, 2024 | marketbeat.com177,051 Shares in G1 Therapeutics, Inc. (NASDAQ:GTHX) Acquired by Panagora Asset Management Inc.Panagora Asset Management Inc. bought a new stake in G1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 177,051 shares of the company's stock, valued at approximately $404,000.September 4, 2024 | marketbeat.comG1 Therapeutics Inc.August 30, 2024 | barrons.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, OBDC, PETQ on Behalf of ShareholdersAugust 20, 2024 | stockhouse.comVanguard Group Inc. Raises Stock Holdings in G1 Therapeutics, Inc. (NASDAQ:GTHX)Vanguard Group Inc. grew its stake in G1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) by 5.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,081,573 shares of the company's stockAugust 16, 2024 | marketbeat.comQ3 2024 EPS Estimates for G1 Therapeutics, Inc. (NASDAQ:GTHX) Raised by AnalystG1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) - Stock analysts at Wedbush raised their Q3 2024 earnings per share estimates for G1 Therapeutics in a research report issued to clients and investors on Thursday, August 8th. Wedbush analyst D. Nierengarten now anticipates that the company will pAugust 12, 2024 | marketbeat.comGTHX SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Tender Offer of G1 Therapeutics, Inc.August 9, 2024 | globenewswire.comHold Rating Affirmed Amid G1 Therapeutics’ Acquisition by PharmacosmosAugust 9, 2024 | markets.businessinsider.comIn $400M deal for Triangle firm, familiar name is largest shareholderAugust 9, 2024 | bizjournals.comNeedham Downgrades G1 Therapeutics (GTHX)August 9, 2024 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of ShareholdersAugust 9, 2024 | globenewswire.comG1 Therapeutics, Inc. to Post Q3 2025 Earnings of ($0.04) Per Share, Wedbush Forecasts (NASDAQ:GTHX)G1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) - Equities researchers at Wedbush dropped their Q3 2025 earnings per share (EPS) estimates for G1 Therapeutics in a research report issued to clients and investors on Wednesday, August 7th. Wedbush analyst D. Nierengarten now forecasts that the coAugust 9, 2024 | marketbeat.comHC Wainwright Lowers G1 Therapeutics (NASDAQ:GTHX) to HoldHC Wainwright downgraded shares of G1 Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday.August 9, 2024 | marketbeat.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Forecasted to Earn FY2027 Earnings of $0.16 Per ShareG1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) - Research analysts at Wedbush increased their FY2027 EPS estimates for G1 Therapeutics in a research note issued to investors on Wednesday, August 7th. Wedbush analyst D. Nierengarten now forecasts that the company will earn $0.16 per share for tAugust 8, 2024 | marketbeat.comG1 Therapeutics (NASDAQ:GTHX) Downgraded by WedbushWedbush lowered shares of G1 Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday.August 8, 2024 | marketbeat.comG1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational HighlightsAugust 8, 2024 | globenewswire.comG1 Therapeutics Shares Hit 52-Week High on Deal to Be AcquiredAugust 7, 2024 | marketwatch.comGTHX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of G1 Therapeutics, Inc. Is Fair to ShareholdersAugust 7, 2024 | stockhouse.comRTP company taken private in $405 million dealAugust 7, 2024 | bizjournals.comG1 Therapeutics To Be Acquired By Pharmacosmos For $7.15/shr In CashAugust 7, 2024 | markets.businessinsider.comG1 Therapeutics Q2 2024 Earnings PreviewAugust 7, 2024 | msn.comRTP drugmaker G1 Therapeutics taken private in $405 million dealAugust 7, 2024 | bizjournals.comG1 Therapeutics surges on merger deal with PharmacosmosAugust 7, 2024 | msn.comG1 Therapeutics (NASDAQ:GTHX) Stock Rating Reaffirmed by Needham & Company LLCNeedham & Company LLC reiterated a "hold" rating on shares of G1 Therapeutics in a research note on Wednesday.August 7, 2024 | marketbeat.comG1 Therapeutics Target of Unusually High Options Trading (NASDAQ:GTHX)G1 Therapeutics, Inc. (NASDAQ:GTHX - Get Free Report) was the target of unusually large options trading activity on Wednesday. Traders bought 4,302 call options on the company. This is an increase of approximately 135% compared to the average daily volume of 1,832 call options.August 7, 2024 | marketbeat.comShareholder Alert: Ademi LLP investigates whether G1 Therapeutics, Inc. has obtained a Fair Price for its Public ShareholdersAugust 7, 2024 | prnewswire.comWhy Is G1 Therapeutics (GTHX) Stock Up 66% Today?August 7, 2024 | investorplace.comPharmacosmos Group to Acquire G1 TherapeuticsAugust 7, 2024 | globenewswire.comG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2024 | globenewswire.comG1 Therapeutics (GTHX) to Release Quarterly Earnings on ThursdayG1 Therapeutics (NASDAQ:GTHX) will be releasing earnings before the market opens on Thursday, August 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=613217)August 1, 2024 | marketbeat.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Short Interest UpdateG1 Therapeutics, Inc. (NASDAQ:GTHX - Get Free Report) was the target of a large increase in short interest in the month of July. As of July 15th, there was short interest totalling 7,030,000 shares, an increase of 23.6% from the June 30th total of 5,690,000 shares. Based on an average trading volume of 1,530,000 shares, the short-interest ratio is presently 4.6 days.July 28, 2024 | marketbeat.comG1 Therapeutics, Inc.'s (NASDAQ:GTHX) top owners are retail investors with 56% stake, while 28% is held by institutionsJuly 26, 2024 | finance.yahoo.comG1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024July 25, 2024 | globenewswire.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Shares Bought by Acadian Asset Management LLCAcadian Asset Management LLC increased its stake in shares of G1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) by 643.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 433,709 shares of the company's stock after purchasJuly 25, 2024 | marketbeat.comG1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025July 15, 2024 | investorplace.comBiotech Bombshell: G1 Therapeutics Stock Is Too Much of a GambleJuly 10, 2024 | investorplace.comBiotech Bombshell: G1 Therapeutics Stock Is Too Much of a GambleJuly 10, 2024 | investorplace.comJohn E. (Jack) Jr. Bailey Sells 7,662 Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) StockJuly 9, 2024 | insidertrades.comG1 Therapeutics Added to the Russell 2000® and 3000® IndexesJuly 1, 2024 | globenewswire.comFY2024 Earnings Forecast for G1 Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:GTHX)G1 Therapeutics, Inc. (NASDAQ:GTHX - Free Report) - Research analysts at HC Wainwright boosted their FY2024 earnings estimates for shares of G1 Therapeutics in a note issued to investors on Tuesday, June 25th. HC Wainwright analyst E. White now anticipates that the company will post earnings of (June 27, 2024 | marketbeat.comNeedham & Company LLC Trims G1 Therapeutics (NASDAQ:GTHX) Target Price to $6.00Needham & Company LLC dropped their price target on shares of G1 Therapeutics from $12.00 to $6.00 and set a "buy" rating on the stock in a research report on Tuesday.June 25, 2024 | marketbeat.comWedbush Reaffirms Outperform Rating for G1 Therapeutics (NASDAQ:GTHX)Wedbush reaffirmed an "outperform" rating and issued a $3.00 target price (down previously from $5.00) on shares of G1 Therapeutics in a research report on Monday.June 24, 2024 | marketbeat.comStock Traders Purchase High Volume of Put Options on G1 Therapeutics (NASDAQ:GTHX)G1 Therapeutics, Inc. (NASDAQ:GTHX - Get Free Report) was the target of unusually large options trading activity on Monday. Investors purchased 3,989 put options on the stock. This represents an increase of approximately 97% compared to the typical daily volume of 2,023 put options.June 24, 2024 | marketbeat.comWhy Is G1 Therapeutics (GTHX) Stock Down 56% Today?June 24, 2024 | investorplace.comG1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)June 24, 2024 | globenewswire.comNeedham & Company LLC Reiterates "Buy" Rating for G1 Therapeutics (NASDAQ:GTHX)Needham & Company LLC reissued a "buy" rating and issued a $12.00 target price on shares of G1 Therapeutics in a report on Thursday.June 13, 2024 | marketbeat.comG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2024 | globenewswire.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Short Interest Up 26.9% in MayG1 Therapeutics, Inc. (NASDAQ:GTHX - Get Free Report) was the target of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 3,590,000 shares, an increase of 26.9% from the April 30th total of 2,830,000 shares. Based on an average daily volume of 1,380,000 shares, the short-interest ratio is presently 2.6 days.June 1, 2024 | marketbeat.com Get G1 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter. Email Address Buy this coin BEFORE Inauguration Day … (Ad)Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office. This could be his favorite coin. GTHX Media Mentions By Week GTHX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GTHX News Sentiment▼0.000.60▲Average Medical News Sentiment GTHX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GTHX Articles This Week▼12▲GTHX Articles Average Week Get G1 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RCUS News Today KNSA News Today IMCR News Today OCUL News Today MESO News Today TVTX News Today NTLA News Today PRAX News Today ARVN News Today DAWN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GTHX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share G1 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
